- Published on
Infectious disease and microbiology – Parvovirus infection
Parvovirus B19 infection is a common viral illness with a wide spectrum of clinical manifestations, ranging from mild childhood disease to severe complications in high-risk groups. It is best known for causing erythema infectiosum (fifth disease), but it can also lead to transient aplastic crisis in patients with chronic hemolytic anemia, chronic anemia in immunocompromised individuals, and serious fetal complications such as hydrops fetalis and fetal death. Notably, it is responsible for the majority of aplastic crises in conditions like sickle cell disease.
The virus has a global distribution, with humans as the only reservoir. Seroprevalence increases with age, reaching 30–60% in adults, and infection commonly occurs in childhood outbreaks, particularly in late winter and early spring. Transmission occurs mainly via respiratory secretions, but can also occur through blood products, vertical (mother-to-fetus) transmission, and rarely nosocomial exposure.
After an incubation period of about one week, viremia develops and is followed by infection of erythroid precursor cells in the bone marrow, leading to temporary suppression of red blood cell production (pure red-cell aplasia). The characteristic rash and joint symptoms appear later and are immune-mediated. In immunocompromised patients, failure to mount an antibody response may result in persistent infection and chronic anemia.
Clinically, infection often begins with mild flu-like symptoms such as fever, malaise, headache, and myalgias. This is followed by the classic “slapped cheek” facial rash, which may spread as a lacy, reticular rash over the extremities. Joint symptoms, particularly symmetric polyarthropathy affecting the hands, wrists, and knees, are more common in adults, especially women. In patients with hemolytic disorders, the presentation may be dominated by severe anemia, often without rash.
Diagnosis in typical childhood cases is clinical, but laboratory confirmation can be achieved through detection of parvovirus-specific IgM antibodies or a rise in IgG titers. In immunocompromised patients, PCR detection of viral DNA is more reliable, as antibody responses may be absent. In aplastic crises, laboratory findings include severe anemia with low reticulocyte count and characteristic bone marrow findings (giant pronormoblasts).
Management is largely supportive, as infection in immunocompetent individuals is usually self-limited. Nonsteroidal anti-inflammatory drugs may help relieve joint symptoms. In severe cases, such as aplastic crisis or chronic anemia, treatment includes blood transfusions and intravenous immunoglobulin (IVIG). In immunocompromised patients, reducing immunosuppression when possible may aid recovery.
Special consideration is required during pregnancy, as fetal infection can result in severe anemia, hydrops fetalis, and fetal death, particularly in the first half of pregnancy. Monitoring with ultrasound and laboratory testing is essential, and intrauterine transfusion may be needed in severe cases.
The prognosis is excellent in healthy individuals, with most cases resolving without complications. However, complications can occur in vulnerable populations and include severe anemia, chronic infection, fetal loss, hepatitis, myocarditis, meningoencephalitis, and hemophagocytic syndrome. Overall, parvovirus B19 infection highlights the contrast between a typically mild childhood illness and its potentially serious impact in high-risk groups.
Parvovirus B19 infection is a common viral illness with a wide spectrum of clinical manifestations, ranging from mild childhood disease to severe complications in high-risk groups. It is best known for causing erythema infectiosum (fifth disease), but it can also lead to transient aplastic crisis in patients with chronic hemolytic anemia, chronic anemia in immunocompromised individuals, and serious fetal complications such as hydrops fetalis and fetal death. Notably, it is responsible for the majority of aplastic crises in conditions like sickle cell disease.
The virus has a global distribution, with humans as the only reservoir. Seroprevalence increases with age, reaching 30–60% in adults, and infection commonly occurs in childhood outbreaks, particularly in late winter and early spring. Transmission occurs mainly via respiratory secretions, but can also occur through blood products, vertical (mother-to-fetus) transmission, and rarely nosocomial exposure.
After an incubation period of about one week, viremia develops and is followed by infection of erythroid precursor cells in the bone marrow, leading to temporary suppression of red blood cell production (pure red-cell aplasia). The characteristic rash and joint symptoms appear later and are immune-mediated. In immunocompromised patients, failure to mount an antibody response may result in persistent infection and chronic anemia.
Clinically, infection often begins with mild flu-like symptoms such as fever, malaise, headache, and myalgias. This is followed by the classic “slapped cheek” facial rash, which may spread as a lacy, reticular rash over the extremities. Joint symptoms, particularly symmetric polyarthropathy affecting the hands, wrists, and knees, are more common in adults, especially women. In patients with hemolytic disorders, the presentation may be dominated by severe anemia, often without rash.
Diagnosis in typical childhood cases is clinical, but laboratory confirmation can be achieved through detection of parvovirus-specific IgM antibodies or a rise in IgG titers. In immunocompromised patients, PCR detection of viral DNA is more reliable, as antibody responses may be absent. In aplastic crises, laboratory findings include severe anemia with low reticulocyte count and characteristic bone marrow findings (giant pronormoblasts).
Management is largely supportive, as infection in immunocompetent individuals is usually self-limited. Nonsteroidal anti-inflammatory drugs may help relieve joint symptoms. In severe cases, such as aplastic crisis or chronic anemia, treatment includes blood transfusions and intravenous immunoglobulin (IVIG). In immunocompromised patients, reducing immunosuppression when possible may aid recovery.
Special consideration is required during pregnancy, as fetal infection can result in severe anemia, hydrops fetalis, and fetal death, particularly in the first half of pregnancy. Monitoring with ultrasound and laboratory testing is essential, and intrauterine transfusion may be needed in severe cases.
The prognosis is excellent in healthy individuals, with most cases resolving without complications. However, complications can occur in vulnerable populations and include severe anemia, chronic infection, fetal loss, hepatitis, myocarditis, meningoencephalitis, and hemophagocytic syndrome. Overall, parvovirus B19 infection highlights the contrast between a typically mild childhood illness and its potentially serious impact in high-risk groups.
0 Comments
